Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Multiple myeloma is the second most common blood cancer in adults. It starts in the white blood cells that are responsible ...

The advent of single-cell omics technologies has revolutionized our understanding of the complex cellular landscape in cancer. Traditional bulk sequencing ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for ...